Gender-specific COMT Val158Met polymorphism association in Spanish schizophrenic patients

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 1, 2010, Pages 79-85

  Hoenicka, Janet ^a,b   Garrido, Elena ^b   Martínez, Isabel ^a,b   Ponce, Guillermo ^a,b   Aragüés, María ^a,b   Rodríguez Jiménez, Roberto ^a,b   España Serrano, Laura ^a   Alvira Botero, Ximena ^a   Santos, Jośe Luis ^c   Rubio, Gabriel ^a,b   Jiménez Arriero, Miguel Ángel ^a,b   Palomo, Tomás ^a,b   Alfonso, S ^d   Bagney, A ^d   Ballester, J ^d   Belloso, J J ^d   Bermu E ^d   Caballero, M ^d   Cano, P ^d   Diez, J ^d   Holgado, P ^d   Muniz M J ^d   Navio M ^d   Ramos, J ^d   Rodriguez Torresano J ^d   Rubio, I ^d   Solera, S ^d   Vega, S ^d   Del Yerro, M J ^d   more..

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c HOSPITAL VIRGEN DE LA LUZ   (Spain)

^d NONE

Author keywords

Catechol O methyltransferase; Gender specificity; Genetic association; Schizophrenia; Val158Met polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; CATECHOL O-METHYLTRANSFERASE; DNA PRIMERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METHIONINE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEX FACTORS; SPAIN; VALINE;

EID: 73949104355     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30957     Document Type: Article

References (46)

1. Abdolmaleky HM, Cheng KH, Faraone SV, Wilcox M, Glatt SJ, Gao F, Smith CL, Shafa R, Aeali B, Carnevale J, et al. 2006. Hypomethylation of MB-COMTpromoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 15(21):3132-3145.
2. APA. 2000. Diagnostic and statistical manual of mental disorders. Washington D.C: Text Revision (DSM-IV-TR).
3. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al. 2004. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75(5):807-821.
4. de Chaldee M, Laurent C, Thibaut F, Martinez M, Samolyk D, Petit M, Campion D, Mallet J. 1999. Linkage disequilibrium on the COMT gene in French schizophrenics and controls. Am J Med Genet 88(5):452-457.
5. Dean K, Murray RM. 2005. Environmental risk factors for psychosis. Dialogues Clin Neurosci 7(1):69-80.
6. Dempster EL, Mill J, Craig IW, Collier DA. 2006. The quantification of COMT mRNA in post mortem cerebellum tissue: Diagnosis, genotype, methylation and expression. BMC Med Genet 7:10.
7. Diez-Martin J, Hoenicka J, Martinez I, Aragues M, Rodriguez-Jimenez R, Jimenez-Arriero MA, Ponce G, Rubio G, Palomo T. 2007. COMT Val158Met polymorphism and schizophrenia in a series of Spanish patients. Med Clin (Barc) 128(2):41-44.
8. Domschke K, Deckert J, O'Donovan MC, Glatt SJ. 2007. Meta-analysis of COMT val158met in panic disorder: Ethnic heterogeneity and gender specificity. Am J Med Genet Part B 144B(5):667-673.
9. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. 2001. Effect ofCOMTVal108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98(12):6917-6922.
10. Ehlis AC, Reif A, Herrmann MJ, Lesch KP, Fallgatter AJ. 2007. Impact of catechol-O-methyltransferase on prefrontal brain functioning in schizophrenia spectrum disorders. Neuropsychopharmacology 32(1):162-170.
11. Fan JB, Zhang CS, GuNF, Li XW, Sun WW, Wang HY, Feng GY, St Clair D, He L. 2005. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biol Psychiatry 57(2):139-144.
12. First MBSR, Gibbon M, Williams JBLB. 1995. Structured Clinical Interview for DSM-IV axis I disorders patient edition (SCID-IP, Version 2.0). New York: Biometric Research, New York State Psychiatric Institute.
13. Goghari VM, Sponheim SR. 2008. Differential association of the COMT Val158Met polymorphism with clinical phenotypes in schizophrenia and bipolar disorder. Schizophr Res 103(1-3):186-191.
14. Gottesman II. 1991. Schizophrenia genesis: The origins of madness. New York: W.H. Freeman.
15. Harrison PJ, Tunbridge EM. 2008. Catechol-O-Methyltransferase (COMT): A gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 33(13):3037-3045.
16. Jiang H, Xie T, Ramsden DB, Ho SL. 2003. Human catechol-O- methyltransferase down-regulation by estradiol. Neuropharmacology 45(7):1011-1018.
17. Koster A, Lajer M, Lindhardt A, Rosenbaum B. 2008. Gender differences in first episode psychosis. Soc Psychiatry Psychiatr Epidemiol 43(12):940-946.
18. Kremer I, Pinto M, Murad I, Muhaheed M, Bannoura I, Muller DJ, Schulze TG, Reshef A, Blanaru M, Gathas S, et al. 2003. Family-based and case-control study of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. Am J Med Genet Part B 119B(1):35-39.
19. LachmanHM,Papolos DF, Saito T,YuYM,Szumlanski CL, Weinshilboum RM. 1996. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6(3):243-250.
20. Li T, Sham PC, Vallada H, Xie T, Tang X, Murray RM, Liu X, Collier DA. 1996. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet 6(3):131-133.
21. Lohoff FW, Weller AE, Bloch PJ, Nall AH, Ferraro TN, Kampman KM, Pettinati HM, Oslin DW, Dackis CA,O'Brien CP, et al. 2008. Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology 33(13):3078-3084.
22. Luo X, Zuo L, Kranzler HR, Wang S, Anton RF, Gelernter J. 2008. Recessive genetic mode of an ADH4 variant in substance dependence in African-Americans: A model of utility of the HWD test. Behav Brain Funct 18(4):42.
23. Mannisto PT, Kaakkola S. 1999. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51(4):593-628.
24. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R, Weinberger DR, Berman KF. 2005. Midbrain dopamine and prefrontal function in humans: Interaction and modulation by COMT genotype. Nat Neurosci 8(5):594-596.
25. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, Mattay VS, Egan M, Weinberger DR. 2006. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 11(9):867-877 797.
26. Munafo MR, Bowes L, Clark TG, Flint J. 2005. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: A meta-analysis of case-control studies. Mol Psychiatry 10(8):765-770.
27. Owen MJ. 2005. Genomic approaches to schizophrenia. Clin Ther 27-(SupplA): S2-S7.
28. Palomo T, Archer T, Kostrzewa RM,Beninger RJ. 2004. Gene-environment interplay in schizopsychotic disorders. Neurotox Res 6(1):1-9.
29. Pelayo-Teran JM, Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, Mata I, Arranz MJ, Leyva-Cobian F, Vazquez-Barquero JL. 2008. Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. Am J Med Genet Part B 147B(5):550-556.
30. Pooley EC, Fineberg N, Harrison PJ. 2007. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: Case-control study and meta-analysis. Mol Psychiatry 12(6):556-561.
31. Pritchard JK, Rosenberg NA. 1999. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65(1):220-228.
32. Pritchard JK, Stephens M, Donnelly P. 2000. Inference of population structure using multilocus genotype data. Genetics 155(2):945-959.
33. Reich DE, Goldstein DB. 2001. Detecting association in a case-control study while correcting for population stratification. Genet Epidemiol 20(1):4-16.
34. Sanchez JJ, Phillips C, Borsting C, Balogh K, Bogus M, Fondevila M, Harrison CD, Musgrave-Brown E, Salas A, Syndercombe-Court D, et al. 2006. A multiplex assay with 52 single nucleotide polymorphisms for human identification. Electrophoresis 27(9):1713-1724.
35. Sanders AR, Rusu I, Duan J, Vander Molen JE, Hou C, Schwab SG, Wildenauer DB, Martinez M, Gejman PV. 2005. Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia. Mol Psychiatry 10(4):353-365.
36. Sazci A, Ergul E, Kucukali I, Kilic G, Kaya G, Kara I. 2004. Catechol-O-methyltransferase gene Val108/158Met polymorphism, and susceptibility to schizophrenia: Association is more significant in women. Brain Res Mol Brain Res 132(1):51-56.
37. Sery O, Didden W, Mikes V, Pitelova R, Znojil V, Zvolsky P. 2006. The association between high-activity COMT allele and alcoholism. Neuro Endocrinol Lett 27(1-2):231-235.
38. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, et al. 2002. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71(6):1296-1302.
39. Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M, Frankle WG, Weinberger DR, Laruelle M, Abi-Dargham A. 2008.COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatry 13(8):821-827.
40. Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, et al. 2008. Large recurrent microdeletions associated with schizophrenia. Nature 455(7210):232-236.
41. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. 1997. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74(4):439-442.
42. Weinshilboum RM, Otterness DM, Szumlanski CL. 1999. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52.
43. Williams NM, Glaser B, Norton N, Williams H, Pierce T, Moskvina V, Monks S, Del Favero J, Goossens D, Rujescu D, et al. 2008. Strong evidence that GNB1L is associated with schizophrenia. Hum Mol Genet 17(4):555-566.
44. Wonodi I, Stine OC, Mitchell BD, Buchanan RW, Thaker GK. 2003. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet Part B 120B(1):47-50.
45. Xie T, Ho SL, Ramsden D. 1999. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 56(1):31-38.
46. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. 2008. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 40(7):880-885.